Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
J Hematol Oncol. 2018 Jan 27;11(1):13. doi: 10.1186/s13045-018-0556-x.
Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin's lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has improved significantly the prognosis of this hematological malignancy, but at the cost of increased toxicities, such as acute toxic death and secondary malignancies. But thanks to a rising understanding of the biology of MCL, the explosion of specifically targeted new efficacious agents, immunotherapy agents, and cellular therapies in the frontline setting, the prognosis of MCL is expected to improve dramatically.The initial treatment of MCL is currently not standardized and the therapeutic landscape of MCL is rapidly evolving. This review provides an extensive overview of the current frontline therapy trials for MCL and presents the results of innovative regimen, including some integrating novel agents and desintensified chemotherapy.
套细胞淋巴瘤（MCL）是一种罕见且无法治愈的非霍奇金淋巴瘤亚型，通常影响老年人。然而，高剂量化疗和自体干细胞移植的应用已经显著改善了这种血液恶性肿瘤的预后，但代价是增加了毒性，如急性毒性死亡和继发性恶性肿瘤。但是，由于对 MCL 生物学的认识不断提高，新型靶向有效药物、免疫治疗药物和细胞治疗药物在一线治疗中的应用不断增加，预计 MCL 的预后将显著改善。目前，MCL 的初始治疗尚未标准化，MCL 的治疗领域正在迅速发展。本综述广泛概述了目前 MCL 的一线治疗试验，并介绍了创新方案的结果，包括一些整合新型药物和减量化疗的方案。
